| 外用他克莫司和吡美莫司的安全性 |
| |
| 引用本文： | 刘苏俊,林麟.外用他克莫司和吡美莫司的安全性[J].国际皮肤性病学杂志,2007,33(1):10-12. |
| |
| 作者姓名： | 刘苏俊 林麟 |
| |
| 作者单位： | 210042,南京,中国医学科学院、中国协和医科大学皮肤病研究所 |
| |
| 摘 要： | 他克莫司和吡美莫司是新型钙调磷酸酶抑制剂药物,其外用制剂可用于治疗特应性皮炎。近年来,对这两种药物的安全性存有争议。现有的资料表明,外用他克莫司和吡美莫司安全性高,不引起皮肤萎缩,经皮吸收极少,无明显的系统免疫抑制作用,不会引起皮肤或系统的感染和肿瘤的发病率升高。
|
| 关 键 词： | 他克莫司 吡美莫司 安全性 |
| 收稿时间： | 2006-05-15 |
Safety profile of topical tacrolimus and pimecrolimus |
| |
| LIU Su-jun,LIN Lin.Safety profile of topical tacrolimus and pimecrolimus[J].International Journal of Dermatology and Venereology,2007,33(1):10-12. |
| |
| Authors: | LIU Su-jun LIN Lin |
| |
| Abstract: | Tacrolimus and pimecrolimus are new calcineurin inhibitors which are topically used in the treatment of atopic dermatitis.There are some debates on the safety of the two drugs recently.In reviewing available data topical tacrolimus and pimecrolimus are safe with no skin atrophy and low percutaneous absorp- tion.There is no evidence suggesting that the immune system is inhibited obviously and the risk of cutaneous or systemic infection and cancer is increased with the application of the two drugs. |
| |
| Keywords: | Tacrolimus Pimecrolimus Safety |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
